Abraxane sNDA Is 505(b)(2) Test, But Panel Has Efficacy, Labeling Questions
Executive Summary
One obstacle to using the 505(b)(2) pathway for approving efficacy supplements appears to be how to characterize an agent's effectiveness in labeling
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PS047545
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
PS047545
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.